Please assess the completion status of the following clinical trial:

Trial Title: A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Down syndrome, except for mosaic Down syndrome~* Available parent or caregiver to attend clinic visits and provide information about the participant's behavior and symptoms~Exclusion Criteria:~* Any primary psychiatric comorbid disorder~* History of infantile spasms, West syndrome, Lennox-Gastaut syndrome, early infantile epileptic encephalopathy, treatment-refractory epilepsy with cognitive/developmental regression, severe head trauma, or central nervous system (CNS) infection~* Seizure event of any type within 12 months prior to Screening or relevant changes in anti-epileptic drugs 6 weeks prior to enrollment~* Significant sleep disruption~* Significant gastrointestinal, renal, hepatic, endocrine, or cardiovascular disease~* New-onset or ongoing hematologic/oncologic disorder~* Severe lactose intolerance~* Participation in another clinical study within 1 month or 6 half-lives prior to first dose, or any extent of participation in Study BP29589 (NCT02451657)

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive matching placebo by mouth (PO) twice daily (BID) for up to 26 weeks.
- RO5186582 120 mg BID (Type: EXPERIMENTAL): Participants will receive RO5186582 at a dosage of 120 milligrams (mg) PO BID for up to 26 weeks.
- RO5186582 40 mg BID (Type: EXPERIMENTAL): Participants will receive RO5186582 at a dosage of 40 mg PO BID for up to 26 weeks.
- RO5186582 60 mg BID (Type: EXPERIMENTAL): Participants will receive RO5186582 at a dosage of 60 mg PO BID for up to 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).